Professor of Surgery, University S Fla College of Medicine
General Surgery
Dr. Vernon K. Sondak, MD
|
|
Give Review
Vernon Sondak practices General Surgery. He went to Boston University School of Medicine. Boston University School of Medicine has a rank of 30 in research and a 52 in primary care He over the years received 4 awards: "America's Top Doctors", "America's Top Doctors for Cancer", "Fellow (FACS)" and "Super Doctor". Vernon Sondak is also a published MD. He has 50 paper published. The most recent paper is: Is a Wider Margin (2cm vs. 1cm) for a 1.01-2.0mm Melanoma Necessary? He is registered with Medicare and accepts Medicare payments.
Publications
- Is a Wider Margin (2 cm vs. 1 cm) for a 1.01-2.0 mm Melanoma Necessary?
- BRAF inhibition for advanced locoRegional BRAF V600E mutant melanoma: a potential neoadjuvant strategy.
- Combination Therapies for Melanoma: A New Standard of Care?
- Ligand-Independent EPHA2 Signaling Drives the Adoption of a Targeted Therapy-Mediated Metastatic Melanoma Phenotype.
- Merkel cell Carcinoma and immunosuppression: what we still need to know.
- Risk-stratified screening for detection of melanoma.
- Sentinel lymph node biopsy is indicated for patients with thick clinically lymph node-negative melanoma.
- Adjuvant Vaccine Immunotherapy of Resected, Clinically Node-Negative Melanoma: Long-term Outcome and Impact of HLA Class I Antigen Expression on Overall Survival.
- Southwest Oncology Group S0008: A Phase III Trial of High-Dose Interferon Alfa-2b Versus Cisplatin, Vinblastine, and Dacarbazine DTIC, Plus Interleukin-2 and Interfero...
- Indications and Options for Systemic Therapy in Melanoma.
- Unusual Presentations of Melanoma: Melanoma of Unknown Primary Site, Melanoma Arising in Childhood, and Melanoma Arising in the Eye and on Mucosal Surfaces.
- Beyond BRAF: where next for melanoma therapy?
- Phase 2 study of RO4929097, a gamma-secretase inhibitor, in metastatic melanoma: SWOG 0933.
- Melanoma: MSLT-1-putting sentinel lymph node biopsy into context.
- Setting the bar for adjuvant treatment of melanoma.
- Unanswered Questions in the Management of Stage I-III Merkel Cell Carcinoma.
- Inhibition of autophagy enhances the effects of the AKT inhibitor MK-2206 when combined with paclitaxel and carboplatin in BRAF wild-type melanoma.
- Relationships among primary tumor size, number of involved nodes, and survival for 8044 cases of Merkel cell Carcinoma.
- Age as a Predictor of Sentinel Node Metastasis among Patients with Localized Melanoma: An Inverse Correlation of Melanoma Mortality and Incidence of Sentinel Node Meta...
- Age as a prognostic factor in patients with localized melanoma and Regional metastases.
- Conjunctival Melanomas Harbor BRAF and NRAS Mutations--Letter.
- Radiotherapy influences local control in patients with desmoplastic melanoma.
- The Society for Immunotherapy of Cancer consensus statement on tumour immunotherapy for the treatment of cutaneous melanoma.
- Cutaneous leiomyosarcoma: treatment and outcomes with a standardized margin of resection.
- Novel treatments for melanoma brain metastases.
- Identifying risk factors using a skin Cancer screening program.
- Pediatric melanoma: Analysis of an international registry.
- Emergence of a squamous cell Carcinoma phenotype following treatment of metastatic basal cell Carcinoma with vismodegib.
- Has targeted therapy for melanoma made chemotherapy obsolete?
- Cutaneous Angiosarcoma: A Single-Institution Experience.
- Single-institution Outcome Experience Using AlloDerm® as Temporary Coverage or Definitive Reconstruction for Cutaneous and Soft Tissue Malignancy Defects.
- Paradoxical oncogenesis-the long-term effects of BRAF inhibition in melanoma.
- Gene Variants in Angiogenesis and Lymphangiogenesis and Cutaneous Melanoma Progression.
- A collision of Diseases: chronic lymphocytic leukemia discovered during lymph node biopsy for melanoma.
- Telomere length and risk of melanoma, squamous cell Carcinoma, and basal cell Carcinoma.
- Targeted therapy in melanoma.
- Desmoplastic Melanoma: Is There a Role for Sentinel Lymph Node Biopsy?
- Combined Analysis of Phase III Trials Evaluating [(99m)Tc]Tilmanocept and Vital Blue Dye for Identification of Sentinel Lymph Nodes in Clinically Node-Negative Cutaneo...
- Case-Control Study of Cutaneous Human Papillomavirus Infection in Basal Cell Carcinoma of the Skin.
- Targeted therapy for melanoma: is double hitting a home run?
- The unique clinical characteristics of melanoma diagnosed in children.
- Sentinel node biopsy is indicated for thin melanomas ≥0.76 mm.
- Surgical management of melanoma-in-Situ using a staged marginal and central excision technique.
- Phase I trial of interleukin-12 plasmid electroporation in patients with metastatic melanoma.
- CTLA-4 blockade with monoclonal antibodies in patients with metastatic Cancer: surgical issues.
- Merkel cell polyomavirus (MCV) T-antigen seroreactivity, MCV DNA in eyebrow hairs, and squamous cell Carcinoma.
- Clinicopathologic Predictors of Survival in Patients with Desmoplastic Melanoma.
- Clonal architectures and driver mutations in metastatic melanomas.
- Integrating molecular biomarkers into current clinical management in melanoma.
Schools
Boston University School Of Medicine
UCLA Med Center
University Of California Los Angeles
Procedures Preformed
- Dressing and-or Debridement of Wound, Infection, or Burn (incl. Negative Pressure Wound Therapy)
- Excision, Shaving, or Destruction of Skin and Subcutaneous Tissue (incl. Mohs Micrographic Surgery), Tissue Transfer
- Laparoscopic Sigmoidectomy With Robotic Assistance
- Lymph Node Biopsy or Excision
- View All
Conditions Treated
- Abdominal Pain
- Adrenal Gland Cancer
- Anal and Rectal Cancer
- Anorectal Abscess
- View All
Doctors Specialties
- General Surgery
Accepted Insurances
Awards
- America's Top Doctors
- America's Top Doctors for Cancer
- Fellow (FACS)
- Super Doctor
Education
-
UCLA Medical Center -
Boston University School of Medicine
Hospital
-
H. Lee Moffitt Cancer Center and Research Institute
Drug Facts
| NPI NUMBER | 1285640821 | |
| NPPES Provider LastName | SONDAK | |
| NPPES Provider FirstName | VERNON | |
| NPPES Provider ZIPCode | 336129416 | |
| NPPES Provider State | FL | |
| Specialty Description | General Surgery | |
| Total Claim Count | 56.0 | |
| Distinct Opioid Count | 1.0 | |
| Opioid Claim Count | 40.0 | |
| Percent Opioid Claims | 71.43 |
Helpful Reviews
Medicare Facts
| National Provider Identifier [NPI] | 1285640821 |
| Last Name Of The Provider | SONDAK |
| First Name Of The Provider | VERNON |
| View All |
Similar Doctors
|
Dr. Vanessa L. Prowler, MD |
|
Dr. Richard G. Picciocca, MD
 This Doctor is OpenDoctor Recommended.
|
|
Dr. John M. Cox, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Lesly A. Dossett, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Brian K. Zebrowski, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. David J. Smith, MD
This Doctor is OpenDoctor Recommended.
|
|
Dr. Jason M. Hechtman, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Jaime E. Sanchez, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Prashant B. Sukharamwala, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Kyle B. Potts, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Scott F. Lentz, MD |
|
|
Dr. Heather M. Bennett, MD |
|
|
Dr. Jacentha L. Buggs, MD
This Doctor is OpenDoctor Recommended.
|
|
|
Dr. Steven M. Lorch, MD |